Given that CRYBMIM has increased affinity for CBP/P300 similar to that of native MYB (5.7 ± 0.2 μM and 4.2 ± 0.5 μM, respectively), we reasoned that its improved activity would now permit detailed kinetic studies to define the specific gene expression programs that are aberrantly activated in AML cells. The gene discussed is CREBBP; the disease is acute myeloid leukemia.